PAREXEL APPOINTS JOSEPHINE HOPPE TO CHIEF INFORMATION OFFICER
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, announced today it has appointed Josephine Hoppe as Corporate Vice President and Chief Information Officer (CIO). Ms. Hoppe is responsible for managing the Company’s information technology (IT) initiatives and integrating technology solutions with business processes on a global basis.
Prior to joining PAREXEL, Ms. Hoppe was the CIO of Pegasystems, a business process management company, where she was responsible for designing and building a comprehensive portfolio of enterprise solutions. Previously, she served as Executive Vice President and CIO of CMGI and as CIO of Addison Wesley Longman.
“PAREXEL’s unique position as both the leading eClinical solutions provider, through our subsidiary Perceptive Informatics, and as one of the world’s largest users of these technologies is an important differentiator in the value we are able to deliver to clients,” said Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL International. “In this regard, we look forward to Jo’s innovation and leadership in helping PAREXEL to achieve the strategic information management objectives of the Company and its clients. She has a proven track record of achievements in the successful development and deployment of IT systems for critical business operations.”
Ms. Hoppe commented, “ I’m proud to join PAREXEL, which is clearly a leader in combining clinical and technology capabilities. I look forward to working with the worldwide IT leadership and staff at PAREXEL to bring even greater efficiency and flexibility to technology-driven solutions that will significantly benefit our clients and employees.”
With more than 20 years of experience in IT, software product development, and operational management, Ms. Hoppe has led technology strategy and implementation efforts at complex, global organizations in a variety of industries. She holds several advisory positions, including serving as President of the Board of Directors for the Society for Information Management, Boston Chapter, and on the Board of Advisors of Future Forward, a technological think-tank sponsored by The Boston Globe columnist Scott Kirsner. She has also been an advisor to the Massachusetts Archive Foundation run by the Secretary of State. Ms. Hoppe is an active member of the Society for Information Management, a national professional organization of CIOs based in the U.S. Her work has been featured in Computerworld and CIO magazine, and she was named as a Finalist for the 2007 Mass Technology Leadership Council CIO of the Year Award, which exemplifies leadership and excellence in business and technology. Ms. Hoppe holds a Master of Science from Goddard College and a Bachelor of Arts from Fairleigh Dickinson University.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has over 9,180 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 as filed with the SEC on November 7, 2008, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.